Association of T Cell and Macrophage Activation with Arterial Vascular Health in HIV

AIDS Research and Human Retroviruses

Volumn 33, Issue 2, 2017, Pages 181-186

  Grome, Heather N ^a   Barnett, Louise ^a   Hagar, Cindy C ^a   Harrison, David G ^a   Kalams, Spyros A ^a   Koethe, John R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cardiovascular; Endothelium; Flow mediated dilation; HIV; Immune activation

Indexed keywords

CD163 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; CD38 DR ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; EFAVIRENZ; EMTRICITABINE; INTERCELLULAR ADHESION MOLECULE 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TENOFOVIR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE;

ADULT; ANTIRETROVIRAL THERAPY; ARTERIAL SMOOTH MUSCLE; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; BODY MASS; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLOW-MEDIATED DILATION TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; MIDDLE AGED; PRIORITY JOURNAL; SMOKING; SMOOTH MUSCLE RELAXATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION; VASCULAR SMOOTH MUSCLE; BLOOD; COMPLICATION; DIAGNOSTIC IMAGING; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PATHOPHYSIOLOGY;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; BRACHIAL ARTERY; CARDIOVASCULAR DISEASES; EMTRICITABINE; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HUMANS; IMMUNOASSAY; INTERCELLULAR ADHESION MOLECULE-1; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MALE; MIDDLE AGED; T-LYMPHOCYTE SUBSETS; TENOFOVIR; ULTRASONOGRAPHY; VASCULAR CELL ADHESION MOLECULE-1;

EID: 85012048726     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2016.0113     Document Type: Article

References (36)

1. Currier JS, Taylor A, Boyd F, et al.: Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003;33:506-512.
2. Triant VA, Lee H, Hadigan C, Grinspoon SK: Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007;92:2506-2512.
3. Cruse B, Cysique LA, Markus R, Brew BJ: Cerebrovascular disease in HIV-infected individuals in the era of highly active antiretroviral therapy. J Neurovirol 2012;18:264-276.
4. Freiberg MS, Chang CC, Kuller LH, et al.: HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013;173:614-622.
5. Womack JA, Chang CC, So-Armah KA, et al.: HIV infection and cardiovascular disease in women. J Am Heart Assoc 2014;3:e001035.
6. Ronsholt FF, Ullum H, Katzenstein TL, Gerstoft J, Ostrowski SR: Persistent inflammation and endothelial activation in HIV-1 infected patients after 12 years of antiretroviral therapy. PLoS One 2013;8:e65182.
7. Subramanian S, Tawakol A, Burdo TH, et al.: Arterial inflammation in patients with HIV. JAMA 2012;308:379-386.
8. Hsue PY, Giri K, Erickson S, et al.: Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation 2004;109:316-319.
9. Pober JS, Sessa WC: Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 2007;7:803-815.
10. Haser GC, Sumpio B: Systemic and cell-specific mechanisms of vasculopathy induced by human immunodeficiency virus and highly active antiretroviral therapy. J Vasc Surg 2016. [Epub ahead of print]; DOI:10.1016/j.jus.2016 .01.036.
11. Kaplan RC, Sinclair E, Landay AL, et al.: T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 2011;203:452-463.
12. Kaplan RC, Sinclair E, Landay AL, et al.: T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis 2011;217:207-213.
13. Karim R, Mack WJ, Kono N, et al.: T-cell activation, both pre-and post-HAART levels, correlates with carotid artery stiffness over 6.5 years among HIV-infected women in the WIHS. J Acquir Immune Defic Syndr 2014;67:349-356.
14. Longenecker CT, Funderburg NT, Jiang Y, et al.: Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIVMed 2013;14:385-390.
15. Torriani FJ, Komarow L, Parker RA, et al.: Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152 s. J Am Coll Cardiol 2008;52:569-576.
16. de Larranaga GF, Bocassi AR, Puga LM, Alonso BS, Benetucci JA: Endothelial markers and HIV infection in the era of highly active antiretroviral treatment. Thromb Res 2003;110:93-98.
17. de Gaetano Donati K, Rabagliati R, Tumbarello M, et al.: Increased soluble markers of endothelial dysfunction in HIV-positive patients under highly active antiretroviral therapy. AIDS 2003;17:765-768.
18. Faulx MD, Wright AT, Hoit BD: Detection of endothelial dysfunction with brachial artery ultrasound scanning. Am Heart J 2003;145:943-951.
19. Juonala M, Viikari JS, Laitinen T, et al.: Interrelations between brachial endothelial function and carotid intimamedia thickness in young adults: The cardiovascular risk in young Finns study. Circulation 2004;110:2918-2923.
20. Shechter M, Shechter A, Koren-Morag N, Feinberg MS, Hiersch L: Usefulness of brachial artery flow-mediated dilation to predict long-term cardiovascular events in subjects without heart disease. Am J Cardiol 2014;113:162-167.
21. Corretti MC, Anderson TJ, Benjamin EJ, et al.: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-265.
22. Savitz DA, Olshan AF: Multiple comparisons and related issues in the interpretation of epidemiologic data. Am J Epidemiol 1995;142:904-908.
23. Benito JM, Lopez M, Lozano S, et al.: Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005;38:373-381.
24. Stein JH, Klein MA, Bellehumeur JL, et al.: Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001;104:257-262.
25. van Wijk JP, de Koning EJ, Cabezas MC, et al.: Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. J Am Coll Cardiol 2006;47:1117-1123.
26. Solages A, Vita JA, Thornton DJ, et al.: Endothelial function in HIV-infected persons. Clin Infect Dis 2006;42:1325-1332.
27. Hunt PW, Brenchley J, Sinclair E, et al.: Relationship between T cell activation and CD4+ T cell count in HIVseropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008;197:126-133.
28. Catalfamo M, Di Mascio M, Hu Z, et al.: HIV infectionassociated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc Natl Acad Sci U S A 2008;105:19851-19856.
29. Catalfamo M, Wilhelm C, Tcheung L, et al.: CD4 and CD8 T cell immune activation during chronic HIV infection: Roles of homeostasis, HIV, type I IFN, and IL-7. J Immunol 2011;186:2106-2116.
30. Ross R: Atherosclerosis is an inflammatory disease. Am Heart J 1999;138:S419-S420.
31. Andersson J, Libby P, Hansson GK: Adaptive immunity and atherosclerosis. Clin Immunol 2010;134:33-46.
32. Schmal H, Czermak BJ, Lentsch AB, et al.: Soluble ICAM-1 activates lung macrophages and enhances lung injury. J Immunol 1998;161:3685-3693.
33. Lukacs NW, Strieter RM, Elner VM, Evanoff HL, BurdickM, Kunkel SL: Intercellular adhesion molecule-1 mediates the expression ofmonocyte-derived MIP-1 alpha duringmonocyteendothelial cell interactions. Blood 1994;83:1174-1178.
34. McCabe SM, Riddle L, Nakamura GR, et al.: sICAM-1 enhances cytokine production stimulated by alloantigen. Cell Immunol 1993;150:364-375.
35. Otto VI, Heinzel-Pleines UE, Gloor SM, Trentz O, Kossmann T, Morganti-Kossmann MC: sICAM-1 and TNFalpha induce MIP-2 with distinct kinetics in astrocytes and brain microvascular endothelial cells. J Neurosci Res 2000;60:733-742.
36. Francisci D, Giannini S, Baldelli F, et al.: HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. AIDS 2009;23:589-596.